Recombinant TNF alpha (Infliximab Biosimilar) anticorps
Aperçu rapide pour Recombinant TNF alpha (Infliximab Biosimilar) anticorps (ABIN7200661)
Antigène
Type d'anticorp
Reactivité
Hôte
Clonalité
Conjugué
Application
Classe de qualité
Clone
-
-
Fonction
- Infliximab Biosimilar, TNF alpha Monoclonal Antibody
-
Specificité
- The monoclonal antibody Infliximab biosimilar specifically binds to the human TNF alpha.
-
Attributs du produit
- Infliximab, a chimeric anti-TNF-α monoclonal antibody, is used to treat psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab interferes TNF-α from binding to its receptor in the cell. Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of autoimmune reaction. Syd Labs also provides the following anti-TNF antibody biosimilar protein:
-
Purification
- Protein A or G affinity column
-
Pureté
- >95 % by reducing SDS-PAGE
-
Stérilité
- 0.2 μm filtered
-
niveau d'endotoxine
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogène
- The monoclonal antibody Infliximab biosimilar was produced in the Infliximab biosimilar CHO stable cell line.
-
Isotype
- IgG1
-
-
-
-
Indications d'application
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Infliximab.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- > 3 mg/mL
-
Buffer
- PBS, pH 7.4, no stabilizers or preservatives.
-
Agent conservateur
- Without preservative
-
Stock
- 4°C,-20 °C
-
Stockage commentaire
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
-
Date de péremption
- 12 months
-
-
- TNF alpha (Infliximab Biosimilar)
-
Autre désignation
- Infliximab Biosimilar
-
Classe de substances
- Biosimilar
Antigène
-